(Press-News.org) Montréal, May 25, 2015 - A team of researchers at the IRCM led by François Robert, PhD, uncovered a critical role for two proteins in chromatin structure. Their breakthrough, recently published in the scientific journal Molecular Cell, helps explain how DNA is organized in our cells. This discovery could lead to a better understanding of what causes certain types of cancer, such as lymphoma.
Dr. Robert and his team study chromatin, the structure composed of DNA and proteins that makes up chromosomes. Its main role is to package DNA molecules containing all the organism's genes into the cell nucleus, which is approximately 20,000 times smaller than the DNA itself.
"This extreme compaction is made possible by proteins called histones, which condense the DNA much like thread is wound around a spool," explains Dr. Robert, Director of the Chromatin and Genomic Expression research unit at the IRCM. "Maintaining an appropriate chromatin structure is essential for normal development and, not surprisingly, defects in chromatin components can lead to several diseases."
Chromatin is carefully organized in such a way that genes remain "accessible" to the various proteins required for gene expression, or the interpretation of the genic information stored in DNA. Chromatin therefore provides the organism with another layer of information, referred to as epigenetic information, which is made available, in part, through specialized histones called histone variants.
"In our laboratory, we study one such histone variant called H2A.Z," says Célia Jeronimo, PhD, research associate in Dr. Robert's laboratory and first author of the study. "H2A.Z is located in specific regions of the gene called promoters, which are involved in controlling gene expression. It is known that H2A.Z is necessary for promoters to function properly."
"With this study, we discovered that two other proteins (FACT and Spt6) play an important role in the location of H2A.Z," adds Dr. Jeronimo. "In fact, we found that these proteins are essential to prevent an accumulation of H2A.Z in inappropriate regions of the gene, which leads to a disorganized chromatin structure."
The study also reveals that inhibiting the inappropriate positioning of H2A.Z is crucial to prevent gene expression defects called "cryptic transcription".
"Inappropriate H2A.Z localization has previously been observed in cancer cells, but little was understood about the consequences of this phenomenon," states Dr. Robert. "Although our study was performed in yeast cells, it suggests that mislocalization of H2A.Z may lead to cryptic transcription in some types of cancer such as lymphoma, and this may contribute to the disease. Our next step is therefore to investigate the possible role of H2A.Z and its associated gene expression defects in cancer cells."
INFORMATION:
About the research project
The research project at the IRCM was supported by the Canadian Institutes of Health Research and a fellowship to Dr. Jeronimo from the L'Oréal-UNESCO for Women in Science Research Excellence. The study was conducted in collaboration with Drs. Craig L. Peterson and Shinya Watanabe from the University of Massachusetts Medical School, as well as Dr. Craig D. Kaplan from Texas A&M University.
For more information, please refer to the article summary published online by Molecular Cell: http://www.cell.com/molecular-cell/abstract/S1097-2765(15)00221-X.
About François Robert
François Robert obtained his PhD in molecular biology from the Université de Sherbrooke. He is Associate IRCM Research Professor, Director of the Chromatin and Genomic Expression research unit, and Director of the Systems Biology and Medicinal Chemistry research division at the IRCM. He is also Associate Research Professor in the Department of Medicine (accreditation in molecular biology) at the Université de Montréal, as well as Adjunct Professor in the Department of Biology at the Université de Sherbrooke. Dr. Robert is a Research Scholar from the Fonds de la recherche du Québec - Santé. For more information, visit http://www.ircm.qc.ca/robert.
About the IRCM
The IRCM is a renowned biomedical research institute located in the heart of Montréal's university district. Founded in 1967, it is currently comprised of 35 research units and four specialized research clinics (cholesterol, cystic fibrosis, diabetes and obesity, hypertension). The IRCM is affiliated with the Université de Montréal, and the IRCM Clinic is associated to the Centre hospitalier de l'Université de Montréal (CHUM). It also maintains a long-standing association with McGill University. The IRCM is funded by the Quebec ministry of Economy, Innovation and Export Trade (Ministère de l'Économie, de l'Innovation et des Exportations).
LOS ANGELES (May 26, 2015) - Biomedical researchers at Cedars-Sinai have invented a tiny drug-delivery system that can identify cancer cell types in the brain through "virtual biopsies" and then attack the molecular structure of the disease.
If laboratory research with mice is borne out in human studies, the results could be used to deliver nano-scale drugs that can distinguish and fight tumor cells in the brain without resorting to surgery.
"Our nanodrug can be engineered to carry a variety of drugs, proteins and genetic materials to attack tumors on several fronts ...
Queen's University PhD student Matt Shultz is researching magnetic, massive stars, and his research has uncovered questions concerning the behaviour of plasma within their magnetospheres.
Drawing upon the extensive dataset assembled by the international Magnetism in Massive Stars (MiMeS) collaboration, led by Mr. Shultz's supervisor, Queen's professor Gregg Wade, along with some of his own observations collected with both the Canada-France-Hawaii Telescope and the European Southern Observatory's Very Large Telescope, Mr. Shultz is conducting the first systematic population ...
Washington, D.C. -- May 26, 2015 -- A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.
"The science behind the concept of blocking the interaction between NPC1 and the virus is solid. Now, it is just a matter of powering through and identifying drugs that can inhibit NPC1 and moving them forward," ...
An international team including scientists from Albert Einstein College of Medicine of Yeshiva University and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) has identified the molecular "lock" that the deadly Ebola virus must pick to gain entry to cells. The findings, made in mice, suggest that drugs blocking entry to this lock could protect against Ebola infection. The study was published in today's edition of the online journal mBio.
The researchers found that the Ebola virus can't infect cells unless it first attaches to a host protein called ...
By unlocking the secrets of a bizarre virus that survives in nearly boiling acid, scientists at the University of Virginia School of Medicine have found a blueprint for battling human disease using DNA clad in near-indestructible armor.
"What's interesting and unusual is being able to see how proteins and DNA can be put together in a way that's absolutely stable under the harshest conditions imaginable," said Edward H. Egelman, PhD, of the UVA Department of Biochemistry and Molecular Genetics. "We've discovered what appears to be a basic mechanism of resistance - to ...
Mitsuyoshi Nakao, Director of the Institute of Molecular Embryology and Genetics in Kumamoto University and Associate Professor Noriko Saitoh revealed that a cluster of defined, non-coding RNAs are mechanistically involved in endocrine therapy resistance in human breast cancer cells. Furthermore, resveratrol, a kind of polyphenol, was found to repress these RNAs and inhibit the proliferative activity of breast cancer cells which had acquired resistance. The work was published in Nature Communications on April 29th, 2015.
Breast cancer is one of the most common types ...
This news release is available in French.
Commuting length, distance, and means are stress factors that can lead to burnout, says Annie Barreck of the University of Montreal's School of Industrial Relations. "A correlation exists between commuting stress factors and the likelihood of suffering from burnout. But their importance varies according to the individual, the conditions in which their trips take place, and the place where the individual works," she explained. Barreck will present her research today at the 83rd congress of the Association francophone pour ...
In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA.
Ninety-four percent of respondents with RA said they cannot do as much as they were able before acquiring the disease. Additionally, 67% said others do not understand the severity of their ...
Protected areas are the cornerstone to prevent species extinctions. The Convention on Biological Diversity have set a target to protect 17% of all terrestrial land by 2020.
Many of the international recommendations concerning protection goals are provided for single countries to take action individually. Researchers in the University of Helsinki, Finland, stress the importance of international collaborations in the protected area expansion process.
"It has been shown that working at the country level is less efficient than promoting transnational collaborations. As ...
New UK research has challenged the assumption that people with rheumatoid arthritis always take their medication as prescribed.
Researchers from the Arthritis Research UK Centre for Epidemiology at The University of Manchester found that 40% of patients scored low on an adherence questionnaire at least once during their time in a recent study, indicating that they might not be taking their expensive biological therapies as regularly as prescribed.
Their research is published online in the journal Rheumatology.
The findings have prompted Arthritis Research UK's head ...
